Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir (BI 201335) + PegIFN/RBV in treatment-naïve chronic hepatitis C
NCT01343888Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virological Response 12 Weeks Post-treatment. Started Apr 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01343888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01343888.